Somewhere between 2022 and 2026, a piece of exercise physiology that used to live in coaching manuals became a mainstream longevity talking point. The claim runs roughly like this: training at a low, conversational intensity — "Zone 2" — builds mitochondria, teaches the body to burn fat efficiently, and is therefore the single most valuable thing a person can do for a long healthspan.
Parts of that are well supported. The specific longevity claim is not, at least not yet. And the honest version of the story turns out to be more interesting than the marketing one, because the evidence points somewhere slightly different from where the trend points.
What "Zone 2" actually means
Zone 2 is a label for an intensity band, not a type of exercise. In the five-zone heart-rate model most watches use, it sits at roughly 60–70% of maximum heart rate: the pace at which you could hold a conversation in full sentences, breathing harder than at rest but nowhere near your limit. In laboratory terms it is the region where blood lactate is still low and stable rather than climbing.
Two things get lost in translation. First, the zone is defined relative to your own physiology, so two people running side by side at identical speeds can be in completely different zones. Second, "Zone 2" is not one fixed thing — three-zone models used in sports science and five-zone models used in consumer devices draw their boundaries in different places, so the same effort can be labelled differently by two apps. Much of the online debate about Zone 2 is really a debate about which model someone is using.
The strong evidence is about fitness, not about a zone
The reason anyone cares about aerobic training at all is the relationship between cardiorespiratory fitness and mortality, and that relationship is about as robust as observational data in this field gets.
In a cohort of 122,007 patients undergoing exercise treadmill testing, followed for a median of 8.4 years with 13,637 deaths recorded, the most fit group had an adjusted hazard ratio of 0.20 (95% CI 0.16–0.24) compared with the least fit. Turned the other way round, low fitness carried a hazard ratio of 5.04 relative to elite fitness — a larger association than coronary artery disease (1.29), smoking (1.41) or diabetes (1.40) in the same analysis. The authors reported no observed upper limit of benefit: even elite performers did better than merely high performers (0.77, 0.63–0.95).
Two caveats belong next to that number. The study was retrospective, and everyone in it had been referred for a treadmill test, which is not the general population. And it is an association: fitter people differ from less fit people in many ways beyond their fitness.
Still, the direction is not seriously disputed. What is disputed is the step people take next — from "aerobic fitness matters enormously" to "therefore this particular heart-rate band is what you should train in". Those are different claims, and only the first one has the big evidence behind it.
Where the mitochondrial argument gets complicated
The mechanistic case for Zone 2 usually goes through mitochondria: low intensity, long duration, more mitochondrial density, better fat oxidation. It is a tidy story. The physiology review literature does not tidily support it.
A review of adaptations to interval training concluded that the signalling which drives mitochondrial biogenesis is largely intensity-dependent, and that the limited work available suggests improvements in mitochondrial content are superior after high-intensity interval training compared with work-matched moderate continuous training. Maximal oxygen uptake also tends to rise more per unit of work performed at higher intensities.
That does not make low-intensity work useless — far from it. It means the idea that low intensity is uniquely the mitochondrial stimulus does not survive contact with the mechanistic literature.
On the outcome side, a meta-analysis of trials in young healthy adults compared continuous endurance training against high-intensity interval training. Both raised maximal oxygen uptake substantially against no-exercise controls, and its authors characterise both of those effects as large. Interval training came out ahead of endurance training, but they characterise that advantage as small next to the gain either approach delivered on its own. Both work, and the gap between them is the smaller part of the story. The population studied was young healthy adults, so it says little about people in their sixties and seventies.
The one long trial that counted deaths
Generation 100 is the study that ought to settle the argument, and the way it failed to is instructive.
Norwegian researchers randomised 1,567 adults aged 70–77 to five years of supervised high-intensity interval training (around 90% of peak heart rate), supervised moderate continuous training (around 70% of peak heart rate — the closest thing in the trial to what is now marketed as Zone 2, though the trial itself did not use that label), or a control group following national activity guidelines. All-cause mortality was the primary endpoint.
The result was null. There was no significant difference in mortality for the combined exercise intervention against control. Control mortality was 4.7%. Interval training against control gave a hazard ratio of 0.63 (0.33–1.20); moderate continuous training against control gave 1.24 (0.73–2.10); interval against moderate gave 0.51 (0.25–1.02). None of those confidence intervals excludes no effect.
The honest reading is not "exercise does not work". The control group was not sedentary — they were active older Norwegians, many of whom took up higher-intensity exercise on their own, which narrowed the gap between the groups and left the trial underpowered for the difference it was looking for. But it remains the closest thing we have to a head-to-head test of whether the moderate zone extends life, and it did not show that it does.
What Zone 2 does reliably
Move away from mortality endpoints and the picture firms up considerably.
Structured aerobic training has a consistent effect on blood-sugar handling. A meta-analysis of 47 randomised trials covering 8,538 participants with diagnosed type 2 diabetes found structured exercise associated with an HbA1c difference of −0.67% (−0.84 to −0.49), with aerobic training at −0.73%. Volume mattered: programmes above 150 minutes a week were associated with −0.89%, those at or below 150 minutes with −0.36%. Physical activity advice on its own, without a structured programme, was associated with no change.
Two things to be careful about here. That evidence comes from people who already have a diagnosed condition, and how much of it transfers to someone whose HbA1c sits comfortably in the normal range is genuinely uncertain — it has not been tested the same way. Anyone with questions about their own blood sugar is best served by a conversation with their GP rather than by extrapolating from a diabetes trial. What the study does say clearly is that accumulated structured volume mattered more than any specific zone, which is an argument for the practicality of Zone 2 — it is the intensity you can sustain for hours a week without wrecking yourself — rather than for its unique biology.
Resting heart rate is the other signal people watch, and it deserves a soft touch. Pooling 46 studies and 1,246,203 people, each 10 beats per minute of higher resting heart rate was associated with an all-cause mortality risk ratio of 1.09 (1.07–1.12) and a cardiovascular risk ratio of 1.08 (1.06–1.10). Above 80 beats per minute, the comparison against the lowest category gave 1.45 (1.34–1.57). The association was graded across categories rather than switching on at a threshold. The authors themselves reported substantial heterogeneity between studies and evidence of publication bias, so this is a soft population-level signal rather than a personal target. Many people see their resting heart rate drift downwards over months of consistent aerobic training, which is part of why it is such a satisfying thing to watch on a wearable, though this varies a great deal between individuals and is not something to expect on a schedule.
Getting the zone right on a wrist
There are two practical problems with the number your watch shows you, and both push in the same direction.
The first is the formula. Most devices derive your zones from an estimated maximum heart rate. A meta-analysis of 351 studies covering 18,712 people, cross-validated in a laboratory sample of 514, put the better estimate at 208 − (0.7 × age), independent of sex and habitual activity level, and showed that the familiar 220 − age formula underestimates maximum heart rate in older adults. For a 60-year-old that is the difference between an assumed maximum of 160 and one of 166 — every zone boundary shifts, and "Zone 2" ends up easier than intended. Both formulas are population averages with wide individual scatter regardless.
The second is the sensor. Wrist-based optical measurement is an estimate, and its accuracy depends on what you are doing. A validation study of a multisensor sports watch against laboratory indirect calorimetry in 30 volunteers found accuracy strongly activity-dependent. The mean absolute percentage error was lowest during sitting and reading, at 9.1%, and highest during household chores, at 31.4%. Averaged across the activities tested, 59.5% of the watch values fell within 20% of the laboratory figure. That study measured energy expenditure rather than heart rate directly, so it is not a measurement of pulse error — but it illustrates the general point that a wrist device produces an estimate whose quality varies with what your arms are doing.
The old talk test survives all of this intact. If you cannot speak in full sentences, you are above the band, whatever the screen says.
Does the mostly-easy, some-hard structure hold up?
The related idea — lots of easy volume plus a small amount of genuinely hard work — has its own small evidence base. A meta-analysis of randomised trials comparing polarised with threshold training intensity distribution found a moderate effect favouring the polarised model on time-trial performance (effect size −0.66, 95% CI −1.17 to −0.15).
The limits are severe: only four trials met the inclusion criteria, three made it into the meta-analysis, methodological quality scored 4–5 out of 10 on the PEDro scale, and the participants were trained endurance athletes with more than two years of endurance experience. The outcome measured was race performance, not health and certainly not lifespan. It supports the structure as a sensible way to organise training. It is not evidence about ageing.
What official guidance actually says
The 2020 World Health Organization guidelines recommend 150–300 minutes of moderate-intensity aerobic activity or 75–150 minutes of vigorous-intensity activity per week for adults, plus muscle-strengthening activity on two or more days, plus reducing sedentary time.
Note the "or". Official guidance is written in the currency of moderate and vigorous activity and treats them as broadly interchangeable — it does not endorse a five-zone model or single out one band as the longevity intensity. That is itself a piece of evidence about how strong the case for a specific zone is considered to be.
Our evidence rating: emerging-to-strong, with a named gap
Strong. Cardiorespiratory fitness is one of the most powerful measured associations with mortality in the literature. Structured aerobic training has a consistent, measurable effect on cardiometabolic markers. The weekly dose in official guidance is well established.
Emerging. Zone 2 as an efficient, sustainable way to accumulate that aerobic volume — plausible, mechanistically reasonable, and consistent with how endurance athletes have trained for decades.
The gap, stated plainly. "Zone 2 is the optimal intensity for longevity" is not supported by head-to-head human outcome data. The single five-year randomised trial with a mortality endpoint was null and numerically unfavourable for the moderate arm. The mechanistic literature, if anything, points the other way on mitochondrial content. And no trial has randomised people to zone-defined training and followed them for decades — nor is one likely to, because the study would take thirty years and cost a fortune.
The practical read: the zone is a fatigue-management tool that lets you do more aerobic work without breaking down. That is a genuinely good reason to use it. It is not a magic band.
How Omniwo helps you measure this
Zone 2 is defined by heart rate, so the useful signals sit in two places: on your wrist and in your blood.
From connected wearables — Oura, WHOOP, Strava, Polar and Apple Health — Omniwo reads resting heart rate and heart-rate variability, which are the two metrics most likely to drift over a training block. Cardio-fitness estimates (VO2 max) come through Apple Health, Strava and Polar; WHOOP provides strain, recovery and heart-rate variability rather than a native VO2 max figure, so we do not present one from it.
On the blood side, HbA1c is the marker the exercise trials described above were tracking. How much it moves in someone whose result is already in the normal range is much less certain than in the diabetes trials described above. It is one of the markers on our cardiovascular panel, and you can read what the number means and how it is interpreted on our HbA1c biomarker page. HbA1c is also one of the inputs to your BioAge score, so a training block shows up there too.
Being straight about the limits: Omniwo does not measure mitochondrial density, lactate threshold or fat-oxidation rate. Those require a laboratory with a metabolic cart and a needle, and no home test kit provides them. What a blood panel gives you is the downstream consequence — how your metabolism and cardiovascular markers are actually behaving — the markers that research has linked to long-term health outcomes, and that you can watch move over time.
A sensible pattern for anyone curious whether their training is doing anything measurable: test, train consistently for a couple of months, test again, and compare. One reading is a snapshot; two readings are a direction. If you want to see what is on the panel, our cardiovascular panel measures HbA1c alongside the other markers in that set.
Omniwo's tests and content are for wellness and educational insight. They are not a medical device, do not diagnose, treat, cure or prevent any disease, and do not replace advice from a qualified healthcare professional.
This article is educational and not medical advice. See our medical disclaimer.
Sources
All sources below are peer-reviewed and indexed in PubMed. Each entry carries its permanent identifiers so every claim can be checked independently.
- Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open. 2018;1(6):e183605. PMID: 30646252. DOI
- MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. The Journal of Physiology. 2017;595(9):2915–2930. PMID: 27748956. DOI
- Milanović Z, Sporiš G, Weston M. Effectiveness of high-intensity interval training (HIT) and continuous endurance training for VO2max improvements: a systematic review and meta-analysis of controlled trials. Sports Medicine. 2015;45(10):1469–1481. PMID: 26243014. DOI
- Stensvold D, Viken H, Steinshamn SL, et al. Effect of exercise training for five years on all cause mortality in older adults — the Generation 100 study: randomised controlled trial. BMJ. 2020;371:m3485. Trial registration NCT01666340. PMID: 33028588. DOI
- Umpierre D, Ribeiro PAB, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305(17):1790–1799. PMID: 21540423. DOI
- Zhang D, Shen X, Qi X. Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis. CMAJ. 2016;188(3):E53–E63. PMID: 26598376. DOI
- Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. Journal of the American College of Cardiology. 2001;37(1):153–156. PMID: 11153730. DOI
- Gilgen-Ammann R, Schweizer T, Wyss T. Accuracy of the multisensory wristwatch Polar Vantage's estimation of energy expenditure in various activities: instrument validation study. JMIR mHealth and uHealth. 2019;7(10):e14534. PMID: 31579020. DOI
- Rosenblat MA, Perrotta AS, Vicenzino B. Polarized vs. threshold training intensity distribution on endurance sport performance: a systematic review and meta-analysis of randomized controlled trials. Journal of Strength and Conditioning Research. 2019;33(12):3491–3500. PMID: 29863593. DOI
- Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine. 2020;54(24):1451–1462. PMID: 33239350. DOI